Hemostemix Inc.

Hemostemix is a pioneering biotechnology company, focused on developing, manufacturing, and commercializing blood-derived cell therapies tailored for various medical conditions in Canada. The company utilizes the patient’s own blood as a non-invasive source of therapeutic cells, allowing for the creation of patient-specific treatments. Their leading product, ACP-01, is currently in a Phase II clinical trial addressing critical limb ischemia. In addition, Hemostemix is actively engaged in developing a range of other cell therapy products, including bone cell precursors, myocardial cell precursors, and neural cell precursors.

Founded in 2006, Hemostemix has garnered significant attention in the biotechnology industry. The company recently received a $325.13K Post-IPO Equity investment on 27 September 2023, underlining the growing interest in their innovative approach. The absence of specific details on the investor(s) in the latest funding round suggests potential confidentiality arrangements or strategic partnerships that may be driving Hemostemix's continued success and expansion.